RxDoctor Payments Data

Janelle Bunce, PA

Physician Assistant · Jamestown, NYNPI 1649203233

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $363,853 of the $565,378 with a category attached, or 64.4%. Teleflex LLC accounts for 88.7% of it on its own, with 43 other manufacturers making up the rest. Reporting peaked in 2022 at $173,332 and has fallen 52.2% since, to $82,785 in 2025. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$565,378in general payments, 2019–2025

Across 1,998 payments — averaging $282.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$501K
  • Axonics, Inc.$18K
  • SRS Medical Systems, Inc.$15K
  • Valencia Technologies Corporation$15K
  • Boston Scientific$8K
  • Dendreon Pharmaceuticals LLC$1K
  • plus $7K from 38 others

What the payments were for

  • Consulting fees$91,51316%
  • Speaking & faculty fees$363,85364%
  • Travel & lodging$68,66712%
  • Food & beverage$40,8307%
  • Education$5160%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$565,378 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$26,687
Medicare patients
131
Services billed
1,418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide24$335,923
MyrbetriqMirabegron115$95,762
GemtesaVibegron97$88,275
OrgovyxRelugolix13$33,339
Silodosin77$7,303
Testosterone28$6,436
Methenamine Hippurate70$4,678
Estradiol66$4,442
Solifenacin Succinate97$3,323
Testosterone Cypionate62$3,225
Potassium Citrate ErPotassium Citrate43$3,092
Cefpodoxime Proxetil25$2,996
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst79$2,345
Tamsulosin Hcl128$2,339
Cephalexin124$1,752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$972$431,686139 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$424$121,614110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Jamestown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →